恒生创新药ETF华泰柏瑞(520500)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

520500 恒生创新药ETF华泰柏瑞

已收盘 06-25 14:59:59

{"stockData":{"symbol":"520500","market":"SH","secType":"STK","nameCN":"恒生创新药ETF华泰柏瑞","latestPrice":1.191,"timestamp":1782370799000,"preClose":1.215,"halted":0,"volume":1311443354,"delay":0,"changeRate":-0.0198,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.024,"latestTime":"06-25 14:59:59","open":1.212,"high":1.219,"low":1.176,"amount":1565000000,"amplitude":0.0354,"askPrice":1.192,"askSize":17325,"bidPrice":1.191,"bidSize":11638,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782437400000},"marketStatusCode":5,"adr":0,"adjPreClose":1.215,"symbolType":"fund","openAndCloseTimeList":[[1782351000000,1782358200000],[1782363600000,1782370800000]],"highLimit":1.337,"lowLimit":1.094,"ibTradeSell":false,"ibTradeBuySell":false,"isCdr":false,"pbRate":0,"committee":-0.201306,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/520500","defaultTab":"news","newsList":[{"id":"2645862117","title":"创新药产业链回购增持密集，恒生创新药ETF华泰柏瑞（520500）最新单日成交额放量突破20亿元！","url":"https://stock-news.laohu8.com/highlight/detail?id=2645862117","media":"新浪基金","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645862117?lang=zh_cn&edition=full","pubTime":"2026-06-24 14:12","pubTimestamp":1782281520,"startTime":"0","endTime":"0","summary":"创新药板块自年内高点以来经历较充分调整，估值与机构持仓均处于相对低位。而随着前期压制市场的BD出海政策传言逐步证伪，叠加多家药企密集回购、7-8月中报业绩窗口临近，创新药赛道关注度正在升温。Wind及交易所数据显示，当前全市场仅有的跟踪恒生创新药指数的ETF产品——恒生创新药ETF华泰柏瑞最新规模突破24.37亿元，份额攀升至20.37亿份、创下历史新高。该ETF近3个交易日成交额呈放量态势、累计吸金超8200万，昨日单日成交额突破20亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-06-24/doc-inientty6298689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","06978","520500","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636152648","title":"152亿美元重磅BD交易再破历史纪录！恒生创新药ETF华泰柏瑞（520500）连续8个交易日获资金净流入","url":"https://stock-news.laohu8.com/highlight/detail?id=2636152648","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636152648?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:39","pubTimestamp":1779259140,"startTime":"0","endTime":"0","summary":"近期BD出海交易再迎重磅大单，叠加学术会议临近召开、财报彰显盈利拐点、政策暖风劲吹、BD出海持续提速，创新药赛道进入密集催化期，相关ETF受资金青睐。　　中国创新药近期迎来重磅BD交易，金额再创历史新高！该协议潜在交易总金额可达约152亿美元、创中国BD历史之最，包含里程碑付款及销售分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-20/doc-inhypnum1753549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636821508","title":"94项中国药企研究入选2026年ASCO年会，恒生创新药ETF华泰柏瑞（520500）基金份额连续创下历史新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636821508","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636821508?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:33","pubTimestamp":1779168780,"startTime":"0","endTime":"0","summary":"近期，创新药板块迎来多重催化：学术会议数据密集、财报彰显盈利拐点、政策暖风劲吹、BD出海持续提速。今日早盘相关ETF交投活跃。2026年ASCO年会将于5月底在芝加哥举行，本届大会中国创新药企业的表现呈现鲜明的“质量驱动”特征。据统计，2026年共34项中国研究入选ASCO口头汇报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-19/doc-inhymcpk3304148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635055632","title":"【ETF动向】5月15日恒生创新药ETF华泰柏瑞基金跌2.07%，份额增加1.13亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635055632?lang=zh_cn&edition=full","pubTime":"2026-05-16 06:32","pubTimestamp":1778884347,"startTime":"0","endTime":"0","summary":"证券之星消息，5月15日，恒生创新药ETF华泰柏瑞基金（520500）跌2.07%，成交额8.26亿元。当日份额增加了1.13亿份，最新份额为18.89亿份，近20个交易日份额增加5.04亿份。当日资金净流入1.07亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为27.18亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.27%，近一个月超额回报为0.31%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051600005979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635852754","title":"【ETF动向】5月13日恒生创新药ETF华泰柏瑞基金跌2.5%，份额增加7850万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2635852754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635852754?lang=zh_cn&edition=full","pubTime":"2026-05-14 06:31","pubTimestamp":1778711510,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日，恒生创新药ETF华泰柏瑞基金（520500）跌2.5%，成交额7.37亿元。当日份额增加了7850万份，最新份额为17.22亿份，近20个交易日份额增加3.36亿份。当日资金净流入6376.21万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为25.78亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.44%，近一个月超额回报为0.22%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400005659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629986199","title":"【ETF动向】4月23日恒生创新药ETF华泰柏瑞基金跌5.39%，份额增加1.08亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629986199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629986199?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:32","pubTimestamp":1776983528,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日，恒生创新药ETF华泰柏瑞基金（520500）跌5.39%，成交额11.12亿元。当日份额增加了1.08亿份，最新份额为15.55亿份，近20个交易日份额增加1.64亿份。当日资金净流入4086.3万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为24.69亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-4.12%，近一个月超额回报为-0.22%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400020401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999604","title":"BD放量+盈利拐点+数据催化，恒生创新药ETF华泰柏瑞、恒生生物科技ETF华泰柏瑞助力布局创新药高景气赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999604","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625999604?lang=zh_cn&edition=full","pubTime":"2026-04-08 11:27","pubTimestamp":1775618820,"startTime":"0","endTime":"0","summary":"2026年以来，中国创新药产业迎来多重利好共振：对外授权交易金额超预期增长，头部企业盈利拐点确立，近期国际学术大会更将密集催化管线数据。同时全球生物医药投融资明确复苏，带动CXO需求向好。当前地缘风险反复，生物科技板块经半年回调后估值处于合理区间，景气度持续上行、配置价值受青睐。　　恒生生物科技ETF华泰柏瑞高度聚焦创新药与CXO两大核心赛道、累计权重达90%，兼顾纳入AI+医疗等前沿领域标的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-08/doc-inhtucsa2855318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","513930","BK1161","520500","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617744591","title":"恒生创新药ETF领涨全市场！关注港股科技底仓工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2617744591","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617744591?lang=zh_cn&edition=full","pubTime":"2026-03-05 11:03","pubTimestamp":1772679819,"startTime":"0","endTime":"0","summary":"ETF方面，恒生创新药ETF\\港股创新药ETF涨幅在A股上市的所有1000只ETF中位于领先地位；覆盖创新药龙头的港股通科技ETF盘中涨幅也超恒生科技ETF。相较恒生科技，多纳入了盈利预期强劲的创新药板块，在互联网、消费电子、新能源车等其他子板块面临一定盈利压力的当下，港股通科技ETF行业由于纳入创新药，分布更均衡，或为更优的港股科技底仓工具配置选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305112229a6a4b72e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305112229a6a4b72e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VXUS","159101","BK4585","520500","BK4588","VT","HSTECH","HSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602031719","title":"华泰柏瑞恒生创新药ETF基金经理变动：李茜不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031719","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602031719?lang=zh_cn&edition=full","pubTime":"2026-01-09 09:31","pubTimestamp":1767922282,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月9日，恒生新药（520500）发布公告，李茜不再担任该基金基金经理，离任日期为2026年1月9日，变更后恒生新药（520500）的基金经理为陈柯含。截止2026年1月8日，恒生新药净值为1.7144，较上一日下跌0.41%，近一年上涨84.46%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900007584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782387294808,"stockEarnings":[{"period":"1week","weight":0.027},{"period":"1month","weight":-0.1265},{"period":"3month","weight":-0.174},{"period":"6month","weight":-0.2486},{"period":"1year","weight":-0.2339},{"period":"ytd","weight":-0.208}],"compareEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":-0.0101},{"period":"3month","weight":0.057},{"period":"6month","weight":0.0371},{"period":"1year","weight":0.2018},{"period":"ytd","weight":0.0358}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒生创新药ETF华泰柏瑞(520500)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒生创新药ETF华泰柏瑞(520500)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒生创新药ETF华泰柏瑞,520500,恒生创新药ETF华泰柏瑞股票,恒生创新药ETF华泰柏瑞股票老虎,恒生创新药ETF华泰柏瑞股票老虎国际,恒生创新药ETF华泰柏瑞行情,恒生创新药ETF华泰柏瑞股票行情,恒生创新药ETF华泰柏瑞股价,恒生创新药ETF华泰柏瑞股市,恒生创新药ETF华泰柏瑞股票价格,恒生创新药ETF华泰柏瑞股票交易,恒生创新药ETF华泰柏瑞股票购买,恒生创新药ETF华泰柏瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒生创新药ETF华泰柏瑞(520500)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒生创新药ETF华泰柏瑞(520500)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}